Vaughan Nelson Investment Management L.P. Decreases Stake in Bruker Corporation $BRKR

Vaughan Nelson Investment Management L.P. lowered its stake in Bruker Corporation (NASDAQ:BRKR) by 21.5% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 1,640,715 shares of the medical research company’s stock after selling 449,440 shares during the quarter. Vaughan Nelson Investment Management L.P. owned 1.08% of Bruker worth $77,294,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Allworth Financial LP raised its holdings in Bruker by 40.6% during the 3rd quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock valued at $29,000 after buying an additional 257 shares during the last quarter. Spire Wealth Management increased its position in shares of Bruker by 85.3% in the third quarter. Spire Wealth Management now owns 1,445 shares of the medical research company’s stock valued at $47,000 after acquiring an additional 665 shares during the period. Jones Financial Companies Lllp increased its position in shares of Bruker by 79.7% in the third quarter. Jones Financial Companies Lllp now owns 2,773 shares of the medical research company’s stock valued at $86,000 after acquiring an additional 1,230 shares during the period. Elevation Point Wealth Partners LLC bought a new position in shares of Bruker during the second quarter valued at about $87,000. Finally, EverSource Wealth Advisors LLC lifted its holdings in Bruker by 51.5% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,770 shares of the medical research company’s stock worth $114,000 after buying an additional 942 shares during the period. Institutional investors own 79.52% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have weighed in on BRKR shares. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Bruker in a research report on Friday. JPMorgan Chase & Co. increased their price objective on Bruker from $50.00 to $55.00 and gave the stock an “overweight” rating in a report on Monday, December 15th. Wolfe Research raised Bruker from a “peer perform” rating to an “outperform” rating and set a $60.00 price objective for the company in a research report on Wednesday, December 10th. Bank of America upped their target price on shares of Bruker from $43.00 to $60.00 and gave the stock a “buy” rating in a research report on Monday, December 15th. Finally, UBS Group reiterated a “neutral” rating and issued a $49.00 price target on shares of Bruker in a research note on Friday, February 13th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $49.77.

Bruker Stock Up 1.7%

BRKR stock opened at $34.31 on Tuesday. The business has a 50 day moving average of $39.77 and a 200 day moving average of $41.31. The firm has a market cap of $5.22 billion, a PE ratio of -228.73, a price-to-earnings-growth ratio of 2.02 and a beta of 1.19. Bruker Corporation has a twelve month low of $28.53 and a twelve month high of $56.22. The company has a quick ratio of 0.87, a current ratio of 1.73 and a debt-to-equity ratio of 0.75.

Bruker (NASDAQ:BRKR) last released its earnings results on Thursday, February 12th. The medical research company reported $0.59 EPS for the quarter, missing the consensus estimate of $0.65 by ($0.06). Bruker had a positive return on equity of 13.56% and a negative net margin of 0.25%.The company had revenue of $977.20 million during the quarter, compared to the consensus estimate of $964.61 million. During the same period last year, the firm posted $0.76 earnings per share. The company’s revenue was down .2% compared to the same quarter last year. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, research analysts forecast that Bruker Corporation will post 2.69 EPS for the current fiscal year.

Bruker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 7th. Investors of record on Monday, March 23rd will be given a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Monday, March 23rd. Bruker’s dividend payout ratio is -133.33%.

Insiders Place Their Bets

In other Bruker news, VP Mark Munch sold 2,000 shares of Bruker stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $35.44, for a total value of $70,880.00. Following the completion of the transaction, the vice president directly owned 128,443 shares of the company’s stock, valued at approximately $4,552,019.92. The trade was a 1.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In the last three months, insiders have sold 11,000 shares of company stock worth $554,280. 27.30% of the stock is currently owned by company insiders.

Bruker Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.